Halozyme Therapeutics halozyme.com


Public list: BIO 2016 (619) Pharma Startups (4733) Cancer Therapeutics (1136)

Halozyme (NASDAQ: HALO) is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology, and dermatology markets.

Halozyme (NASDAQ: HALO) is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology, and dermatology markets.

Company (IPO / Went public)

Phone: 858-794-8889

Fax:

11388 Sorrento Valley Road

San Diego, 92121
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Halozyme Therapeutics $20.3M May 10, 2007

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Halozyme Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Ritchie Capital ManagementHedge FundGeneva, Illinois, United StatesUnattributed VC
Colt VenturesVenture CapitalDallas, Texas, United StatesUnattributed VC
Cimarron Biomedical InvestorsUnattributed VC
Roche Venture FundCorporate VentureBasel, SwitzerlandUnattributed VC - II
GSV CapitalVenture CapitalWoodside, California, United StatesUnattributed VC
See all 6 investors

Board Members

There is no Competitors data available for this company. Please select another tab.